Artiva Biotherapeutics (NASDAQ:ARTV) Coverage Initiated by Analysts at Needham & Company LLC

Needham & Company LLC started coverage on shares of Artiva Biotherapeutics (NASDAQ:ARTV) in a report released on Tuesday, MarketBeat.com reports. The brokerage set a “buy” rating and a $23.00 price target on the stock. Needham & Company LLC’s price target indicates a potential upside of 101.22% from the company’s previous close.

Artiva Biotherapeutics Price Performance

Artiva Biotherapeutics stock opened at $11.43 on Tuesday. Artiva Biotherapeutics has a one year low of $10.50 and a one year high of $16.00.

Insider Buying and Selling

In other Artiva Biotherapeutics news, Director Yong-Jun Huh purchased 2,083,332 shares of the firm’s stock in a transaction on Monday, July 22nd. The shares were acquired at an average cost of $12.00 per share, with a total value of $24,999,984.00. Following the completion of the acquisition, the director now directly owns 3,306,900 shares in the company, valued at $39,682,800. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, Director Yong-Jun Huh acquired 2,083,332 shares of the business’s stock in a transaction dated Monday, July 22nd. The stock was purchased at an average price of $12.00 per share, for a total transaction of $24,999,984.00. Following the completion of the transaction, the director now directly owns 3,306,900 shares in the company, valued at approximately $39,682,800. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Global Strategic Fund I. Venbio purchased 416,666 shares of the company’s stock in a transaction that occurred on Monday, July 22nd. The stock was bought at an average price of $12.00 per share, with a total value of $4,999,992.00. Following the transaction, the insider now owns 1,936,637 shares of the company’s stock, valued at approximately $23,239,644. The disclosure for this purchase can be found here.

About Artiva Biotherapeutics

Artiva Biotherapeutics Inc is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. The company’s lead program includes AlloNK(R). Artiva Biotherapeutics Inc is based in SAN DIEGO.